FDA Extends Review Of orBec For Acute GI Graft-Versus-Host Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
DOR BioPharma, meanwhile, has launched a Phase II trial of the oral beclomethasone dipropionate product in the prophylactic GVHD setting.
You may also be interested in...
Osiris/Genzyme Anticipates Approval Of Stem Cell Therapy Prochymal By 2010
Osiris begins the FDA submission process for its mesenchymal stem cell therapy Prochymal this quarter, making a late-2009 approval of the world's first stem cell therapy a possibility if the agency grants a six-month review, and a first-cycle approval
Osiris/Genzyme Anticipates Approval Of Stem Cell Therapy Prochymal By 2010
Osiris begins the FDA submission process for its mesenchymal stem cell therapy Prochymal this quarter, making a late-2009 approval of the world's first stem cell therapy a possibility if the agency grants a six-month review, and a first-cycle approval
Osiris/Genzyme Anticipate Approval Of Stem Cell Therapy Prochymal By 2010
Submission for graft-versus-host disease indication begins under a rolling BLA this quarter, with final data due at mid-year and a possible six-month review for the first therapy of its kind.